Open AccessMolecular Therapeutic Cancer Peptides: A Closer Look at Bovine Lactoferricin
Author(s) -
Idris Zubairu Sadiq,
K. Babagana,
Dauda Danlami,
Lawi Isa Abdullahi,
Amir Riyaz Khan
Publication year - 2018
Publication title -
asian journal of biochemistry, genetics and molecular biology
Language(s) - English
Resource type - Journals
ISSN - 2582-3698
DOI - 10.9734/ajbgmb/2018/v1i2471
Subject(s) - cancer cell , cancer research , cancer , apoptosis , multiple drug resistance , melanoma , medicine , biology , pharmacology , drug resistance , microbiology and biotechnology , biochemistry
Background: In spite of the progress that was recorded in the development of anticancer drugs, challenges continue to rises particularly due to resistance of the cancer chemotherapies and low sensitivity of the commercially available anticancer drugs.
Methodology: collection and review of available literatures.
Results: Bovine lactoferricin (LfcinB) is a cationic peptide with broad spectrum antimicrobial and anticancer activity. It also shows promising activity against many varieties of cancer cells including colon carcinoma cells, melanoma, fibrosarcoma, monocytic leukemic cells and neuroblastoma. It is unaffected by multidrug resistance mechanisms seen with conventional chemotherapeutic drugs, and displays a higher specificity for cancer cells versus normal cells in comparison to conventional chemotherapy.
Conclusion: LfcinB exhibit strong antitumor activity effectively penetrating cell membrane, activating caspases and induce apoptosis to cancer cells.